Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 4/20 | 0.38 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22775863 | 0.85 | RAF1 (0.37) | RAF1LCKBRD9CA1CA2 | |
| SCHEMBL22774651 | 0.84 | RAF1 (0.36) | RAF1LCKBRD9CA1CA2 | |
| SCHEMBL22774629 | 0.82 | LMNA (0.40) | RAF1LCKCA1CA2RXFP1 | |
| SCHEMBL22774877 | 0.82 | RAF1 (0.35) | RAF1LCKCA1CA2RXFP1 | |
| SCHEMBL22774759 | 0.81 | LCK (0.41) | LCKBRD9CA1CA2CA12 | |
| SCHEMBL22774975 | 0.80 | BRAF (0.37) | RAF1LCKCA1CA2METAP1 | |
| SCHEMBL22775051 | 0.79 | LCK (0.40) | LCKBRD9CA1CA2CA12 | |
| SCHEMBL8737207 | 0.79 | RAF1 (0.41) | RAF1LCKBRD9RXFP1 | |
| SCHEMBL22774665 | 0.79 | LCK (0.43) | LCKBRD9CA1CA2CA12 | |
| SCHEMBL20894299 | 0.78 | DAO (0.46) | LCKBRD9CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624023-B2 | Sulfonylurea derivatives and uses thereof | NodThera Limited (GB) | 2026-05-12 | — | — | US | disclosed |
| EP-3983407-B1 | SULFONYLUREA DERIVATIVES AND USES THEREOF | NODTHERA LTD (GB) | 2025-11-12 | — | — | EP | disclosed |
| US-20230083495-A1 | SULFONYLUREA DERIVATIVES AND USES THEREOF | NodThera Limited (GB) | 2023-03-16 | — | — | US | disclosed |
| EP-3983407-A1 | SULFONYLUREA DERIVATIVES AND USES THEREOF | Nodthera Limited (GB) | 2022-04-20 | — | — | EP | disclosed |
| CN-114222739-A | Sulfonylurea derivatives and use thereof | 诺瑟拉有限公司 | 2022-03-22 | — | — | CN | disclosed |
| WO-2020249664-A1 | SULFONYLUREA DERIVATIVES AND USES THEREOF | NodThera Limited (GB) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020249664-A1 | SULFONYLUREA DERIVATIVES AND USES THEREOF | NodThera Limited (GB) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624023-B2 | Sulfonylurea derivatives and uses thereof | PYCARD, NOD1, NLRP3 | RAF1 688/4885LCK 2942/4885BRD9 1755/4885 |
| US-20230083495-A1 | SULFONYLUREA DERIVATIVES AND USES THEREOF | IL1B, NOD1, IL1A | RAF1 353/4885LCK 2511/4885BRD9 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.